Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation.
The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.
Copelan
E
E
Bone Marrow Transplantation Program, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, OH 43210, USA. copelan-1@medctr.osu.edu
Hoshaw-Woodard
S
S
Elder
P
P
Penza
S
S
Farag
S
S
Marcucci
G
G
Lin
T
T
Ezzone
S
S
Scholl
M D
MD
Bechtel
T
T
Lemeshow
S
S
Avalos
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000150:complications / Q000628:therapy; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods; D006801:Humans; D015994:Incidence; D007938:Leukemia / Q000139:chemically induced*; D008223:Lymphoma / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D009436:Neural Tube Defects / Q000139:chemically induced*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D011336:Probability; D014182:Transplantation, Autologous
D005047:Etoposide